Amgen cancer vaccine due for FDA decision by Oct. 27; GAVI pledges top $7.5B;

> After a three-month delay in its FDA review, Amgen ($AMGN) is expecting a regulatory decision on its cancer vaccine, T-Vec, by Oct. 27. Release

> The GAVI Pledging Conference in Berlin saw new pledges totaling $7.54 billion. Report

> GlaxoSmithKline's ($GSK) Ebola vaccine is safe and generates an immune response, researchers have found. Report

> Three different recombinant protective antigen vaccines formulated with Immunovaccine's DepoVax tech protected animals against a lethal anthrax challenge after one vaccination. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

> A unit of China's Hualan Biological has received government approval to run clinical trials of its H7N9 vaccine. Report

> Tau-based vaccines could transform early Alzheimer's disease treatment, according to GlobalData. Release

And Finally... "Customized soap bubbles" could transform vaccine delivery. More

 

 

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.